Research Paper Volume 14, Issue 12 pp 5271—5291
Molecular subtypes, prognostic and immunotherapeutic relevant gene signatures mediated by DNA methylation regulators in hepatocellular carcinoma
Figure 6. The value of DMS in predicting clinical outcomes in patients with hepatocellular carcinoma. (A) Differences in tumor burden mutation between low and high DMS groups. (B) The correlation between tumor burden mutation and DMS score. (C) Multivariate cox regression analysis for DMS in predicting patient’s survival in TCGA-LIHC cohort. (D) GSEA enrichment analysis showing the activated biological pathways in patients with low DMS. All data analyses were based on the TCGA-LIHC cohort. Cor, correlation.